+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 40 Actively Recruiting clinical trials

R

Actively Recruiting

Researchers are evaluating the use of olaparib, a PARP inhibitor, as a maintenance treatment following surgery and chemotherapy in patients with pancreatic cancer that has been surgically removed and who have a pathogenic mutation in BRCA1, BRCA2, or PALB2. This phase II randomized trial aims to determine if adding olaparib improves relapse-free survival compared to placebo. The study also explores overall survival and treatment effects based on genetic mutation types and prior chemotherapy regimens. Participants are randomly assigned to receive either olaparib or a placebo taken orally twice daily in 28-day cycles for up to 12 cycles, provided there is no disease progression or unacceptable side effects. Throughout the study, patients undergo CT or MRI scans and have blood samples collected regularly. After completing treatment, patients are followed for up to 10 years with scheduled visits at 30 days post-treatment, every 4 months during the first year, and every 6 months for years 2 through 10. During the trial, participants are closely monitored through imaging and blood tests to assess disease recurrence and overall survival. The primary outcome measures relapse-free survival from randomization up to 44 months, while secondary outcomes include long-term survival and comparisons of treatment effects based on mutation type and chemotherapy received. Safety and disease status are assessed regularly to track treatment impact and progression over an extended follow-up period.

Age: 18Years +All GendersPhase 2
456 locations
B

Actively Recruiting

Healthy Volunteer

Researchers are collecting blood and tissue samples from people with and without cancer to help develop and evaluate tests for early cancer detection. This observational study aims to create a blinded reference set of blood samples from cancer and non-cancer patients to validate new blood-based multi-cancer early detection tests. The study also evaluates test performance at the time of initial cancer diagnosis by tumor type and clinical stage. Participants complete a questionnaire at the start of the study and provide blood samples at registration and again 12 months later. Patients diagnosed with cancer may also provide tissue samples at these same times. The study collects these biospecimens to help researchers study and validate early cancer detection assays in the laboratory. During the study, participants are monitored with follow-up at one year after enrollment. Researchers assess the quality and usefulness of the collected blood samples as a blinded reference set for cancer detection tests. The main outcome is the provision of these samples over up to one year, with additional evaluation of test performance by tumor type and stage. Participants involvement includes questionnaires, blood draws, and possible tissue sample collection, with no treatment interventions involved.

Age: 40Years - 75YearsAll Genders
751 locations
N

Actively Recruiting

Researchers are collecting biological samples and medical data from patients who experience serious side effects after receiving immunotherapy treatments for cancer. This observational study aims to build a national collection of these samples and data to help future research better predict, prevent, and manage these immune-related adverse events, rare infections, or rapid tumor growth. Participants provide tissue, blood, and optionally stool samples if they experience colitis, shortly after confirmation of a severe immune-related side effect and again one month later. Their medical records will be reviewed for up to one year to gather detailed clinical information. This study does not involve administering treatments but focuses on collecting data and samples from those already treated with immuno-oncology therapies. During the study, participants undergo sample collections at registration and one month later. Researchers will review medical records over a year to monitor health outcomes and side effects. The main measurement is establishing the biorepository of samples and data for future studies. Participation duration can last up to one year with periodic assessments based on medical record review and sample collection.

All AgesAll Genders
630 locations
P

Actively Recruiting

Researchers are evaluating combinations of targeted drugs in people with advanced non-small cell lung cancer that has spread and shows specific changes in the EGFR and MET genes. This phase II Lung-MAP trial focuses on patients whose cancer has progressed after treatment with osimertinib and aims to compare the effectiveness of combining capmatinib, osimertinib, and ramucirumab. The study also investigates safety, response rates, and survival outcomes while collecting biological samples for further analysis. Participants are randomly assigned to one of two groups. One group receives capmatinib and osimertinib as oral medications plus ramucirumab given intravenously, while the other group receives only capmatinib and osimertinib orally. During the trial, patients undergo regular CT or MRI scans and blood sample collections to monitor their disease and treatment effects. The study includes detailed assessments of tumor responses and side effects over time. Throughout the trial, participants will have scans and blood tests at scheduled intervals to assess disease progression and treatment impact. Researchers will monitor progression-free survival as the main outcome, along with response duration and toxicity. Blood samples are also collected to study circulating tumor DNA. The study continues up to three years, with ongoing safety and efficacy evaluations. Participants must meet specific health criteria and provide informed consent before joining.

Age: 18Years +All GendersPhase 2
454 locations
E

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the impact of the Cost Communication and Financial Navigation CostCOM intervention on adherence to cancer care and financial burden among patients with malignant solid tumors. This study compares the effects of enhanced usual care and the CostCOM program, which offers financial counseling and resource connections to reduce financial barriers and stress. The study aims to assess cost-related non-adherence, financial hardship, worry, quality of life, and satisfaction with care over 12 months. Participants are randomly assigned to one of two groups one group receives a brochure about financial navigation services, while the other group receives usual financial care plus CostCOM counseling sessions lasting about one hour within 30 days of enrollment and again at 3, 6, and 12 months. Non-patient participants involved in the study complete surveys and participate in in-depth interviews between 15 and 39 months after the first patient enrollment. During the study, patients complete surveys at baseline and at 3, 6, and 12 months to report on financial worry, quality of life, and satisfaction with care. Researchers track adherence to cancer treatment and financial outcomes over one year. Non-patient participants contribute by completing surveys and interviews to provide insights into the use and experience of the CostCOM intervention. The total participation time extends up to 12 months for patients and up to 39 months for non-patient participants.

All AgesAll GendersPhase Not Applicable
391 locations
E

Actively Recruiting

This research aims to evaluate the effectiveness and safety of an investigational eye drop solution called Apraclonidine Ophthalmic Solution, 0.125% Unit Dose Preservative Free, compared to a placebo vehicle solution in adults experiencing eye redness due to minor irritations. The study targets adults with ocular redness and focuses on measuring changes in redness after treatment. It is a Phase 3, randomized, double-blind clinical trial sponsored by Alcon Research. Participants will receive a single dose of the study treatment, one drop in each eye on Day 1. The study includes two groups one receiving the investigational Apraclonidine solution and the other receiving a vehicle placebo. The treatment is given during an in-office visit, and eye redness is assessed before and after instillation at specific timepoints on Day 1 and Day 2. Participants are expected to attend three in-office visits over about one week. Assessments include investigator-rated redness scores at baseline and at several times after treatment, including 1 minute, 15 minutes, 14 hours, and 16 hours post-instillation. Safety and efficacy are monitored through these evaluations. The total study period covers from treatment through follow-up assessments, concluding around one week after the first dose.

Age: 18Years +All GendersPhase 3
9 locations
S

Actively Recruiting

Healthy Volunteer

Researchers are evaluating a novel spectacle lens to control myopia progression in young children aged 6 to 8 years. This randomized, controlled, double-masked study aims to validate results from previous trials by comparing the new spectacle lens with a standard single vision, impact-resistant lens. The 12-month results will help predict the treatments effectiveness over three years. Participants are randomly assigned to one of two groups one group will wear the new experimental spectacle lenses, and the other will wear standard single vision lenses. Both types of lenses are impact-resistant. The study requires children to wear their assigned spectacles for at least 10 hours daily, except during sleep, swimming, or other activities where wearing glasses is unsafe or impractical. Children will be involved in the study for 24 months, during which their vision will be regularly checked through tests including spherical equivalent refraction, axial length measurement, and visual acuity assessments. The study monitors how well the lenses control myopia progression and ensures safety by tracking any ocular or systemic conditions. Parent or guardian consent is required for participation.

Age: 6Years - 8YearsAll GendersPhase Not Applicable
14 locations
P

Actively Recruiting

Researchers are evaluating whether adding adjuvant chemotherapy to ovarian function suppression plus endocrine therapy improves invasive breast cancer-free survival in premenopausal women with early-stage estrogen receptor-positive, HER2-negative breast cancer and specific recurrence scores. This Phase III trial addresses a critical need for better treatment options in younger women, who face higher risks of breast cancer recurrence and mortality. Participants will receive one of two treatment approaches ovarian function suppression combined with an aromatase inhibitor for five years, or chemotherapy followed by the same hormonal treatment. The choice of chemotherapy, aromatase inhibitor, and ovarian suppression method is determined by the investigator, with options such as goserelin, leuprolide, or triptorelin administered monthly or every three months. Endocrine therapy beyond five years is at the investigators discretion, and bilateral oophorectomy may replace ovarian suppression if desired. During the trial, participants will be monitored for invasive breast cancer-free survival over 11 years following randomization. Additional outcomes include overall survival, disease-free survival, distant recurrence, and treatment-related symptoms such as menopausal effects and pain during aromatase inhibitor therapy. The study involves regular assessments to evaluate these outcomes and ensure participant safety throughout the extended follow-up period.

Age: 18Years - 60YearsFEMALEPhase 3
1276 locations
A

Actively Recruiting

Healthy Volunteer

Researchers are evaluating an online educational program called Current Together After Cancer CTAC to see if it helps colorectal cancer survivors who had surgery receive follow-up care that matches current guidelines. This phase III trial focuses on patients with stage II or III colorectal cancer who have had their tumors surgically removed. The study aims to improve patients knowledge about surveillance, their confidence in managing follow-up care, and satisfaction with the involvement of a supporter in their care. Patients in the trial are randomly assigned to one of two groups. One group and their supporter get access to the CTAC intervention website, which contains educational content and interactive modules related to colorectal cancer surveillance. The other group and their supporter receive access to a general health education website. Participants may review their assigned website as often as they like for up to 16 months. During the study, participants will complete questionnaires at baseline, 3 months, and 16 months to assess knowledge, self-efficacy, cancer worry, preferences, and satisfaction with supporter engagement. Researchers will measure whether patients receive colorectal cancer surveillance aligned with guidelines at 16 months. The study also explores how supporters participation relates to patient outcomes. Participants may be contacted via email or phone for study activities and are encouraged to complete all scheduled assessments.

Age: 18Years +All GendersPhase 3
384 locations
E

Actively Recruiting

Researchers are evaluating the use of Lacrifill, a chemically crosslinked hyaluronic acid hydrogel device, to prevent dry eye symptoms in adults who have recently undergone unilateral cataract surgery. Dry Eye Disease is a multifactorial condition causing discomfort, visual disturbances, and tear film instability, often worsened by ocular surgery that can damage corneal nerves and the ocular surface. This Phase 4 study focuses on preventing post-operative dry eye symptoms by comparing Lacrifill to standard saline eye drops in patients who have cataract surgery scheduled for both eyes. Participants will be randomly assigned to receive either Lacrifill or saline eye drops as a control. Lacrifill is designed to occlude tear drainage by being placed in the tear ducts, while saline drops represent the current standard care for post-cataract surgery dry eye symptoms. Both treatments will be administered following the manufacturers instructions. The study monitors patients through post-operative visits at one month and three months to evaluate dry eye symptom changes. During the study, participants will have their dry eye symptoms assessed through the Ocular Surface Disease Index OSDI scores and eye dryness visual analog scale VAS scores before treatment and at one and three months after surgery. Researchers will monitor changes in tear film and ocular surface health to determine the effectiveness of Lacrifill in reducing dry eye symptoms after cataract surgery. The total study period extends from screening through follow-up visits up to three months post-operation, with safety and symptom progress carefully tracked.

Age: 18Years - 80YearsAll GendersPhase 4
2 locations

1-10 of 40

1